Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Previous studies of the association between tenofovir and the coronavirus have yielded mixed results.
A study from the Leukemia & Lymphoma Society finds that antibody production varies widely across blood cancer types.
Two new studies come to different conclusions about the risk for severe illness and death.
The results point the way toward a universal coronavirus vaccine that could prevent future pandemics.
Rapid test results are needed to interrupt the chain of coronavirus transmission.
Prolonged delays in cancer screening for low-income women during the pandemic threaten to increase existing health disparities.
The immune response to the single-shot Johnson & Johnson vaccine remained robust against variants of SARS-CoV-2.
Some people with blood cancers, however, may not be as well protected.
These findings, however, may reflect regional attitudes in Utah and the surrounding area.
Disruptions in access to treatment and harm reduction services could set back effort to eliminate hep C in the U.S.
People who received a canarypox vector vaccine regimen were no less likely than placebo recipients to acquire HIV.
An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.
Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.
Low-barrier care and access to multiple services in one place can improve outcomes for people experiencing homelessness or unstable housing.
The results challenge initial concerns that chemotherapy and other treatments were too dangerous to continue during the pandemic.
Researchers found antibodies against the virus that causes COVID-19 in blood samples collected as early as January 2020.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.